Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - aġenti li jaġixxu fuq is-sistema renin-angiotensin - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - iperkalemija - - mediċini għal-kura tal-iperkalimja u ' l-iperphosphatemija - veltassa huwa indikat għall-kura ta 'iperkalimja fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - idebenone - atrofija ottika, ereditarja, leber - psikostimulanti oħrajn u nootropics, psychoanaleptics, - raxone huwa indikat għall-kura ta 'indeboliment tal-vista f'pazjenti adolexxenti u adulti b'neurpatija ottika ereditarja leber (lhon).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

centocor b.v. - idebenone - friedreich ataxia - psychoanaleptics, - it-trattament tal-friedreich’atassja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - spironolactone - dijuretiċi - klieb - għal użu flimkien ma 'terapija standard (inkluż appoġġ dijuretiku, fejn meħtieġ) għat-trattament ta' insuffiċjenza tal-qalb konġestiva kkawżata minn rigurġitazzjoni valvulari fil-klieb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - sistema kardjovaskulari - klieb - għat-trattament ta 'insuffiċjenza tal-qalb konġestiva kkawżata minn mard valvulari klementi deġenerattiv fil-klieb (b'appoġġ dijuretiku kif xieraq).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosoppressanti - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorjatika arthritiscosentyx, waħdu jew f'taħlita ma 'methotrexate (mtx), huwa indikat għall-kura ta' artrite psorjatika attiva f'pazjenti adulti meta r-rispons għall-preċedenti li timmodifika l-marda anti rewmatiċi tad-droga (dmard) it-terapija kienet inadegwata. assjali aksjali (axspa)ankylosing spondylitis (as, radjografiku assjali aksjali)cosentyx huwa indikat għat-trattament ta ' ankylosing spondylitis attiva fl-adulti li ma kellhomx rispons xieraq għat-terapija konvenzjonali. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - immunosoppressanti - jekk jogħġbok irreferi għad-dokument ta 'informazzjoni dwar il-prodott.